14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CLRB ranks #10651 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Cellectar Biosciences Stock Forecast NASDAQ:CLRB

$0.54 (-8.44%)

Volume: 557k

Closed: Jan 21, 2022

Hollow Logo Score: -8.263

Cellectar Biosciences Stock Forecast

$0.54 (-8.44%)

Volume: 557k

Closed: Jan 21, 2022

Score Hollow Logo -8.263

Cellectar Biosciences Company Profile

3301 Agriculture Drive

Madison WI 53716



Industry: Biotechnology

Sector: Healthcare

Cellectar Biosciences


Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. It offers CLR 131, a PDC radiotherapeutic product candidate and is currently being evaluated in a Phase I study for the treatment of relapse or refractory multiple myeloma; CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease ; CLR 124, a cancer-targeting positron emission tomography (PET) imaging PDC for the selective detection of tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting NIR-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE